Natera has delivered a very large 3 year share price gain, so the obvious question is whether the current valuation is still grounded in the cash flows the business can generate. With expectations now shaped by high profile recognition for its cancer and kidney testing platforms, the stock invites a closer look at what investors are really paying for.
- Over the past 3 years, Natera has produced a very large total return, which places extra weight on whether the underlying cash flows can support a much higher equity value.
- Fresh clinical and real world data on the Signatera and Renasight testing suites can influence how investors think about future adoption, timing of potential cash inflows and the level of spending needed to support that growth.
- If you'd rather focus on sales, this one's for you. See why Natera's 21.9x P/S tells a different valuation story.
The issue now is whether the Discounted Cash Flow (DCF) based intrinsic value implied by Natera's cash flows lines up with a market price shaped by rapid share price gains and high profile product milestones.
If you are weighing whether Natera's recent 3 year run is justified by its cash flows, it can help to compare that question across 29 high quality undervalued stocks.
Does Natera Look Undervalued on Cash Flow?
The Discounted Cash Flow model here projects what Natera might return to shareholders based on future free cash flows. On the latest twelve month view, the group generated about $84.3 million of free cash flow, with the DCF framework assuming those cash flows grow meaningfully into the 2030s rather than flattening out.
Those projections indicate a recovering and then growing cash flow profile, with forecast annual free cash flows moving into the low single digit $ billions by 2030 in this model. On that basis, the DCF projections put Natera's estimated intrinsic value substantially above the current share price of $410.82. Because the Signatera Genome data featured in high profile ESMO presentations points to wider clinical use cases, the market enthusiasm embedded in the recent share price move lines up with a cash flow story that already assumes a strong adoption curve. Find out what Natera could be worth using our Discounted Cash Flow (DCF) estimate.
The Natera Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Natera sit between the valuation model and the share price, and explain which future paths for growth, margins and earnings would need to occur for the stock to be worth materially more or materially less than it is today on the market, all housed on the Community page. Where a single ratio or DCF output gives you one headline figure, these narratives unpack the future that figure relies on so you can watch how it unfolds against real results over time.
Community views on Natera are split between one group that sees more upside in the current setup and another that sees expectations already reflected in the price.
Bull case: 16% undervalued
"The accumulating longitudinal multi-modal genomic dataset, now one of the world's largest, will allow Natera to enable personalized digital twin simulations…"
Discover why this Narrative puts Natera at 16% undervalued.
Bear case: roughly fairly valued
"Heavy investment needs, regulatory hurdles, intense competition, and reimbursement challenges create persistent profitability and growth risks across Natera's core diagnostic markets…"
Explore why this Narrative puts Natera at roughly fairly valued.
One more Natera check that sits beside the share price
Cash flow models tell you what the business might produce, but the people choosing where every dollar goes and how they are rewarded can tilt that outcome in very different directions. See who runs Natera and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com